SCHEMBL13102471

SCHEMBL13102471

CSCCNC(=O)c1cccc(NNC(=O)OC(C)(C)C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
HPGD P15428 3/20 0.48
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
TP53 P04637 1/20 0.48
NFKB1 P19838 1/20 0.48
MAPK1 P28482 1/20 0.48
NFKB2 Q00653 1/20 0.48
RELA Q04206 1/20 0.48
ALDH1A1 P00352 3/20 0.44
LMNA P02545 3/20 0.44
PRMT5 O14744 1/20 0.43
WDR77 Q9BQA1 1/20 0.43
MAPT P10636 1/20 0.42
KMT2A Q03164 1/20 0.41
KAT6A Q92794 1/20 0.41
PAX8 Q06710 1/20 0.39
GAA P10253 1/20 0.38
TP53BP1 Q12888 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13102454 0.86 MAPT (0.58) SMN1; SMN2HPGDTP53ALDH1A1LMNA
SCHEMBL3400562 0.83 LMNA (0.48) L3MBTL1SMN1; SMN2HPGDNPC1RAB9A
SCHEMBL7262423 0.80 ACACB (0.58) PRMT5WDR77KMT2A
SCHEMBL536638 0.78 ALDH1A1 (0.51) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL29378002 0.78 ALDH1A1 (0.51) SMN1; SMN2NPC1RAB9AALDH1A1MAPT
SCHEMBL12574371 0.77 SMN1; SMN2 (0.62) L3MBTL1SMN1; SMN2HPGDNPC1RAB9A
SCHEMBL537132 0.76 NPC1 (0.51) L3MBTL1SMN1; SMN2HPGDNPC1RAB9A
SCHEMBL7257964 0.76 RAB9A (0.51) SMN1; SMN2HPGDNPC1RAB9ATP53
SCHEMBL5694862 0.75 MEN1 (0.43) L3MBTL1NPC1RAB9AALDH1A1LMNA
SCHEMBL284764 0.75 SMN1; SMN2 (0.55) L3MBTL1SMN1; SMN2HPGDALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130237507-A1 Novel Amide Compounds ASTRAZENECA AB INTELLECTUAL PROPERTY (GB) 2013-09-12 US disclosed
WO-2010114471-A1 NOVEL AMIDE DERIVATIVES OF STEROIDAL[3,2-C]PYRAZOLE COMPOUNDS WITH GLUCOCORTICOID ACTIVITY ASTRAZENECA AB (SE) 2010-10-07 WO disclosed
US-20100256104-A1 NOVEL AMIDE COMPOUNDS ASTRAZENECA R&D (SE) 2010-10-07 US disclosed
US-20100256104-A1 NOVEL AMIDE COMPOUNDS ASTRAZENECA R&D (SE) 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256104-A1 NOVEL AMIDE COMPOUNDS H1-4, H1-3, H1-5 L3MBTL1 2875/4885SMN1; SMN2 2473/4885HPGD 2753/4885
US-20130237507-A1 Novel Amide Compounds H1-4, H1-3, H1-5 L3MBTL1 2680/4885SMN1; SMN2 2389/4885HPGD 2788/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.